EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT

Víctor Torrecillas-Mayayo, Aina Oliver-Caldes, Nuria Martínez-Cibrian, Nil Albiol, Luis Gerardo Rodríguez-Lobato, Marta Español-Rego, Valentín Ortiz-Maldonado, Laura Rosiñol, Natalia Tovar, Sergio Navarro-Velasquez, Paola Charry, Daniel Munárriz und 10 weitere

Annals of Hematology · 12.05.2026 · 105 (7)

DOI: 10.1007/s00277-026-07063-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 12.05.2026. Verfasst von Víctor Torrecillas-Mayayo und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: POEMS Syndrome, B-Cell Maturation Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació Institució dels Centres de Recerca de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) syndrome is a rare plasma cell disorder with diverse multisystem manifestations. Autologous stem cell transplantation (ASCT) is the preferred front-line therapy when feasible, but relapsed/refractory (RR) cases after ASCT failure lack effective salvage options. B-cell maturation antigen (BCMA)-directed CAR-T cell therapy has revolutionised multiple myeloma (MM) treatment. Given the shared BCMA expression on clonal plasma cells between MM and POEMS, CAR-T cell therapy is also a biologically compelling strategy for POEMS syndrome [1]. However, there are only two previous case reports of CAR-T cell therapy in POEMS [3,4], none involving patients with prior ASCT failure. We report a 54-year-old male with RR-POEMS progressing after two previous ASCT failures who received an academic point-of-care BCMA-directed CAR-T cell therapy (ARI0002h) via fractionated infusion. No cytokine release syndrome (CRS) or neurotoxicity (ICANS) occurred. At 3 months, the patient achieved a measurable residual disease (MRD)-negative complete haematological response (CR H ) by Next Generation Flow (NGF) with a sensitivity of 10⁻⁶ and a radiological CR. Responses have been sustained for 10 months. Serum BCMA (sBCMA) levels declined dynamically in parallel with haematological response, suggesting potential utility as a novel monitoring biomarker in POEMS. This case supports BCMA-directed CAR-T therapy as a safe and effective salvage strategy in RR-POEMS following ASCT failure, even in an aggressive disease context. Clinical trial registration: Not aplicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

POEMS SyndromeB-Cell Maturation AntigenImmunotherapy, AdoptiveHumansMaleMiddle AgedRemission InductionNeoplasm, ResidualBiomarkersRecurrenceReceptors, Chimeric Antigen

Stichwörter der Autor:innen

BCMACAR-TPOEMS syndrome

Substanzen

B-Cell Maturation AntigenTNFRSF17 protein, humanBiomarkersReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
  • Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. CFERNAN1@clinic.cat.

Förderung

  • Fundació Institució dels Centres de Recerca de Catalunya

Zitieren

APA

Torrecillas-Mayayo, V., Oliver-Caldes, A., Martínez-Cibrian, N., Albiol, N., Rodríguez-Lobato, L. G., Español-Rego, M., Ortiz-Maldonado, V., Rosiñol, L., Tovar, N., Navarro-Velasquez, S., Charry, P., Munárriz, D., Mateos, J. M., Jimenez-Mira, C., Moreno, D. F., Montoro, M., Ayora, P., Delgado, J., Juan, M., …, & Fernández de Larrea, C. (2026). Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07063-4

Vancouver

Torrecillas-Mayayo V, Oliver-Caldes A, Martínez-Cibrian N, Albiol N, Rodríguez-Lobato LG, Español-Rego M, et al. Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07063-4

BibTeX
@article{TorrecillasMayayo2026,
  author = {Torrecillas-Mayayo, Víctor and Oliver-Caldes, Aina and Martínez-Cibrian, Nuria and Albiol, Nil and Rodríguez-Lobato, Luis Gerardo and Español-Rego, Marta and Ortiz-Maldonado, Valentín and Rosiñol, Laura and Tovar, Natalia and Navarro-Velasquez, Sergio and Charry, Paola and Munárriz, Daniel and Mateos, Jose Miguel and Jimenez-Mira, Carlos and Moreno, David F and Montoro, Mercedes and Ayora, Pilar and Delgado, Julio and Juan, Manel and González-Navarro, Azucena and Cibeira, Maria Teresa and Fernández de Larrea, Carlos},
  title = {Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {7},
  doi = {10.1007/s00277-026-07063-4}
}
Kostenlos starten →